Korsana Biosciences to Participate in Upcoming Investor Conferences
Korsana Biosciences (KRSA) management will participate in four investor conferences, beginning with Guggenheim’s Healthcare Innovation Conference on November 9, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Korsana Biosciences (KRSA) management will participate in four investor conferences, beginning with Guggenheim’s Healthcare Innovation Conference on November 9, 2026.
Other appearances include Stifel on November 10, UBS on November 16 and Jefferies London on November 17. Live webcasts will be available through the company’s investor website, with replays archived for 90 days following the events.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WALTHAM, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Korsana Biosciences, Inc. (“Korsana” or the “Company”) (Nasdaq: KRSA), a biotechnology company discovering and developing novel therapies to reduce the burden of neurodegenerative diseases, today announced that management will participate in the following upcoming investor conferences.
- Guggenheim 3rd Annual Healthcare Innovation Conference: Fireside chat on Monday, November 9, 2026, at 10:00 a.m. ET in Boston, MA.
- Stifel 2026 Healthcare Conference: Fireside chat on Tuesday, November 10, 2026, at 1:20 p.m. ET in New York, NY.
- UBS Global Biopharma Conference 2026: Fireside chat on Monday, November 16, 2026, at 3:20 p.m. GMT in London, UK.
- Jefferies London Healthcare Conference: Presentation on Tuesday, November 17, 2026, at 3:00 p.m. GMT in London, UK.
Live webcasts of the presentations will be available in the Investors section of the Company’s website at https://investors.korsana.com/news-events/events-presentations. Replays of the webcasts will be archived on the Company’s website for 90 days following the events.
About Korsana Biosciences
Korsana Biosciences is committed to building best-in-class therapeutics with the goal of reducing the burden of neurodegenerative diseases for patients and caregivers. The Company’s lead program, KRSA-028, is a next-generation shuttled antibody targeting amyloid beta for the treatment of Alzheimer’s disease. KRSA-028 leverages Therapeutic Targeting (THETA™), a novel CNS shuttle technology developed in partnership with Paragon Therapeutics and designed to enable dramatically higher drug concentrations in the brain and overcome the limitations of earlier shuttle technologies. In addition, Korsana is advancing a pipeline of innovative therapies for neurodegenerative diseases. For more information, please visit www.korsana.com and follow the Company on LinkedIn.
Investor and Media Contact:
Eva Stroynowski
IR@korsana.com
Media@korsana.com
